Amplification and overexpression of E2F3 in human bladder cancer

Feber, Andrew, Clark, Jeremy, Goodwin, Graham, Dodson, Andrew R, Smith, Paul H, Fletcher, Anne, Edwards, Sandra, Flohr, Penny, Falconer, Alison, Roe, Toby, Kovacs, Gyula, Dennis, Nening, Fisher, Cyril, Wooster, Richard, Huddart, Robert, Foster, Christopher S and Cooper, Colin S (2004) Amplification and overexpression of E2F3 in human bladder cancer. Oncogene, 23 (8). pp. 1627-30. ISSN 0950-9232

Full text not available from this repository. (Request a copy)

Abstract

We demonstrate that, in human bladder cancer, amplification of the E2F3 gene, located at 6p22, is associated with overexpression of its encoded mRNA transcripts and high levels of expression of E2F3 protein. Immunohistochemical analyses of E2F3 protein levels have established that around one-third (33/101) of primary transitional cell carcinomas of the bladder overexpress nuclear E2F3 protein, with the proportion of tumours containing overexpressed nuclear E2F3 increasing with tumour stage and grade. When considered together with the established role of E2F3 in cell cycle progression, these results suggest that the E2F3 gene represents a candidate bladder cancer oncogene that is activated by DNA amplification and overexpression.

Item Type: Article
Uncontrolled Keywords: base sequence,carcinoma, transitional cell,cell line, tumor,cell nucleus,chromosome mapping,chromosomes, human, pair 6,dna, neoplasm,e2f3 transcription factor,gene amplification,gene expression regulation, neoplastic,humans,immunohistochemistry,neoplasm staging,nucleic acid hybridization,oligonucleotide array sequence analysis,rna, messenger,transcription factors,urinary bladder neoplasms
Faculty \ School: Faculty of Science > School of Biological Sciences
Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 06 Jan 2014 14:12
Last Modified: 24 Jul 2019 19:29
URI: https://ueaeprints.uea.ac.uk/id/eprint/46165
DOI: 10.1038/sj.onc.1207274

Actions (login required)

View Item View Item